University Hospital Ostrava, - Department of Internal Medicine and Cardiology
Ostrava, Czech Republic, 70852, Czechia
Location status: Recruiting
NCT Number: NCT05963126
Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. Modified human urine Fetuin A (urine Fetuin A) with specific modification in urine (Fetuin A) can earlier predict the progression of kidney disease in patients with diabetes. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.
Interested in participating?
Request Info18 year–100 year
All sexes
Observational
Ostrava, Czech Republic, 70852, Czechia
Location status: Recruiting
Arterial hypertension and diabetes are the most common cause of chronic kidney disease. Commonly used parameters for the evaluation of renal function (plasma creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) are sensitive to advanced kidney disease. Parameters predicting early kidney impairment are still lacking. Modified human urine Fetuin A with specific modification in urine (urine Fetuin A) presents a new biomarker that seems to be promising in the early prediction of kidney disease in patients with diabetes without microalbuminuria. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention.
Time frame: 1 year
Decline of glomerular filtration rate in 1-year follow-up of each patient in a total of 3 visits at times: 0 months, 6 months, and 12 months.
Time frame: 1 year
Evaluation of urine biomarker DNLite IVD103 and its ability to predict deterioration of renal function defined as a decline of glomerular filtration rate in patients with arterial hypertension, resistant arterial hypertension, and secondary hypertension. Diabetic nephropathy in vitro diagnostics (DNLite IVD103) is a colorimetric immunoassay intended for quantitative measurement of unique Fetuin-A with specific post-translational modification in human urine.
Time frame: 1 year
Evaluation of urine biomarker DNLite IVD103 and its ability to predict deterioration of renal function defined in patients with manifested cardiovascular disease, dyslipidemia (yes/no).
Time frame: 1 year
Evaluation of the correlation of biomarker DNLite IVD103 in patients' plasma and in urine (yes/no).
Interested in participating?
Request InfoUniversity Hospital Ostrava
Other
Modified Urine Fetuin A as a Predictor of Deterioration of Renal Function in Patients With Resistant and Non-resistant Hypertension
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05881447
Albuminuria, Anemia
Bagamoyo, Coast Region, Tanzania
View Trial DetailsNCT06428825
Arterial Hypertension, Cardiovascular Diseases
Mannheim, Baden-Wurttemberg, Germany
View Trial DetailsNCT07396792
Anemia, Arrhythmias, Cardiac
View Trial DetailsNCT05286632
Abnormalities, Multiple, Albuminuria
Bari, Italy
View Trial Details